Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine is a promising biopharmaceutical company with a solid pipeline targeting diseases related to red blood cells. Their recent Phase 2 data on selcodebart for the treatment of anemia in myelofibrosis (MF) and chronic kidney disease (CKD) showed promising response rates and they plan to hold an end-of-Phase 2 meeting with the FDA by the end of the year. Additionally, they have a collaboration with Roche and a potential 2032 launch for DISC-3405 in sickle cell disease. With a Buy rating and a price target of $120, Disc has the potential to deliver significant value to investors, but key risks include regulatory approval, commercialization, and financial challenges as they are not yet profitable.

Bears say

Disc Medicine is facing significant challenges and risks in its path to success, with its pipeline still in early stages and only preliminary data available for its lead programs. While the potential for upside exists in the shorter term with the potential early readout of PV data in 3Q26, there are still many unknowns about the clinical efficacy and potential of DISC-3405 and other programs in development, leaving a negative outlook for the company's stock in the longer term.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Aug 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.